Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH9017 in Chinese Participants With Overweight and Obesity
NCT06830343Phase 1Recruiting
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SYH9017 in obesity and Overweight (5 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Incidence of Adverse Events up to 140 days. Started Feb 2025; status: recruiting.
02
Drugs
SYH9017
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06830343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830343.